BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9524620)

  • 1. Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer.
    Birkenhake S; Martus P; Kühn R; Schrott KM; Sauer R
    Strahlenther Onkol; 1998 Mar; 174(3):121-7. PubMed ID: 9524620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
    Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy is an effective treatment for high-risk T1-bladder cancer.
    Rödel C; Dunst J; Grabenbauer GG; Kühn R; Papadopoulos T; Schrott KM; Sauer R
    Strahlenther Onkol; 2001 Feb; 177(2):82-8; discussion 89. PubMed ID: 11233839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
    Cobo M; Delgado R; Gil S; Herruzo I; Baena V; Carabante F; Moreno P; Ruiz JL; Bretón JJ; Del Rosal JM; Fuentes C; Moreno P; García E; Villar E; Contreras J; Alés I; Benavides M
    Clin Transl Oncol; 2006 Dec; 8(12):903-11. PubMed ID: 17169764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
    Asadauskiene J; Aleknavicius E; Zelviene TP; Jankevicius F
    Medicina (Kaunas); 2006; 42(10):781-7. PubMed ID: 17090976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
    Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil.
    Rödel C; Grabenbauer GG; Kühn R; Zörcher T; Papadopoulos T; Dunst J; Schrott KM; Sauer R
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1303-9. PubMed ID: 11955743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Radiochemotherapy for invasive bladder cancer : An update].
    Tselis N; Prott FJ; Ott O; Weiss C; Rödel C
    Urologe A; 2018 Jun; 57(6):679-685. PubMed ID: 29651707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive bladder cancer: organ preservation by radiochemotherapy.
    Rödel C; Grabenbauer GG; Kühn R; Dunst J; Papadopoulos T; Schrott KM; Sauer R
    Front Radiat Ther Oncol; 2002; 36():118-30. PubMed ID: 11842742
    [No Abstract]   [Full Text] [Related]  

  • 13. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results.
    Birkenhake S; Leykamm S; Martus P; Sauer R
    Strahlenther Onkol; 1999 Mar; 175(3):97-101. PubMed ID: 10093610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radiotherapy in the interdisciplinary approach to the treatment of bladder carcinoma].
    Dunst J
    Strahlenther Onkol; 1991 Oct; 167(10):563-80. PubMed ID: 1948642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
    Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
    Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
    Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.